Evidence map›Paper›PMID 40334661›Full record

ArticleCell reports. Medicine2025

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.

Yan Xu, James Chih-Hsin Yang, Yanqiu Zhao, Ludovic Doucet, Jianying Zhou, Yongsheng Wang, David Planchard, Yun Fan, Bo Jin, Zhigang Han and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Yan XuPeking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
James Chih-Hsin YangNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.
Yanqiu ZhaoAffiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Ludovic DoucetInstitut de Cancérologie de l'Ouest (ICO) - René Gauducheau, Saint-Herblain, France.
Jianying ZhouThe First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yongsheng WangWest China Hospital, Sichuan University, Chengdu, China.
David PlanchardGustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Paris, France.
Yun FanZhejiang Cancer Hospital, Hangzhou, China.
Bo JinThe First Hospital of China Medical University, Shenyang, China.
Zhigang HanThe Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
Laurent GreillierCHU Hôpital de la Timone, Marseille, France.
Julien MazieresCHU de Toulouse - Hôpital Larrey, Toulouse, France.
Meili SunCentral Hospital Affiliated to Shandong First Medical University, Jinan, China.
Ying HuBeijing Chest Hospital, Capital Medical University, Beijing, China.
Xia SongShanxi Provincial Cancer Hospital, Taiyuan, China.
Cuimin DingThe Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Lin WuHunan Cancer Hospital, Changsha, China.
Kejing TangThe First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Li LiangPeking University Third Hospital, Beijing, China.
Yu YaoThe First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ying ChengJilin Cancer Hospital, Changchun, China.
Yong HeArmy Medical Center of PLA, Chongqing, China.
Bruna Pellini FerreiraH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
François GhiringhelliCentre Georges François Leclerc, Dijon, France.
Enriqueta FelipVall d'Hebron Institut d'Oncologia, Barcelona, Spain.
Joaquim Bosch-BarreraInstitut Catala d'Oncologia de Girona (ICO Girona), Girona, Spain.
Anwen LiuThe Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yan YuHarbin Medical University Cancer Hospital, Harbin, China.
Xiaorong DongUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Junzhen GaoThe Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
D Ross CamidgeUniversity of Colorado Hospital, Anschutz Cancer Pavilion, Aurora, CO, USA.
Weiqi NianChongqing Cancer Hospital, Chongqing, China.
Chengzhi ZhouThe First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Runxiang YangYunnan Cancer Hospital, Kunming, China.
Thomas JohnPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Bo GaoBlacktown Hospital, Sydney, NSW, Australia.
Lyudmila BazhenovaUniversity of California, San Diego (UCSD), Moores Cancer Center, La Jolla, CA, USA.
Misako NagasakaUniversity of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange, CA, USA.
Jianghong WangChongqing University Cancer Hospital, Chongqing, China.
Xiubao RenTianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Fei XuThe First Affiliated Hospital of Nanchang University, Nanchang, China.
Wen LiThe Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Dahai ZhaoThe Second Hospital of Anhui Medical University, Hefei, China.
Huijie WangFudan University Shanghai Cancer Center, Shanghai, China.
Si SunFudan University Shanghai Cancer Center, Shanghai, China.
Jian'an HuangThe First Affiliated Hospital of Soochow University, Suzhou, China.
Xuehua ZhuDizal Pharmaceutical, Shanghai, China.
Li ZhengDizal Pharmaceutical, Shanghai, China.
Pasi A JänneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mengzhao WangPeking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: mengzhaowang@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is a report of biomarker analysis for sunvozertinib, a leading epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion mutation (exon20ins) non-small cell lung cancer (NSCLC). There is a positive correlation between positive EGFR exon20ins in plasma circulating tumor DNA (ctDNA) and advanced disease. Shorter progression-free survival and lower objective response rate (45.8% vs. 68.0%) were observed in patients with positive EGFR exon20ins compared to those with negative status. Droplet digital PCR analysis showed that the EGFR exon20ins allele in ctDNA decreased over time in 85.7% of patients, with the earliest clearance occurred after 1 week of sunvozertinib treatment. Acquired EGFR C797S is identified as a potential on-target resistance mutation to sunvozertinib. Finally, efforts are undertaken to investigate therapeutic approaches that aim to overcome the putative acquired resistance to sunvozertinib.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsMutagenesis, InsertionalAgedCirculating Tumor DNADrug Resistance, NeoplasmErbB ReceptorsExonsFemaleHumansMaleMiddle AgedPrognosisProtein Kinase InhibitorsBiomarkers, TumorCirculating Tumor DNAEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsbiomarkerEGFR exon20insNSCLCsunvozertinib

Identifiers

PMID40334661
PMCPMC12147912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.